You are here: Industry Insights > Natco Pharma

News List

Natco Pharma board okays acquiring 1 per cent in Canadian arm expresspharma
March 29, 2021
The board of directors of the company at their meeting approved to acquire 0.96 per cent stake in Natco Pharma Canada.
NATCO gets US FDA approval for Pomalidomide capsules expresspharma
November 16, 2020
Natco Pharma announced that its marketing partner, Breckenridge Pharmaceutical, has received final approval for its Abbreviated New Drug Application (ANDA) for Pomalidomide Capsules, from the US Food and Drug Administration {USFDA).
Dapnat launch to boost Natco’s presence in India’s diabetes market but concerted efforts required, s expresspharma
April 29, 2020
Natco is a new player within the cardiovascular and diabetes therapeutic space, launching its Cardiology and Diabetic (CnD) division in early 2017.
Natco Pharma gets USFDA approval for Visakhapatnam facility expresspharma
April 29, 2020
The company did not disclose the product approved by the USFDA to be produced from the facility.
Natco faces double whammy, falling profit and FDA plant violations fiercepharma
August 13, 2019
India’s Natco Pharma, which has seen a substantial hit to its profits, says it is looking to China and emerging markets for future growth as headwinds in the U.S. slow revenues there.
US FDA issues six observations to Natco Pharma’s API facility near Hyderabad expresspharma
August 13, 2019
Natco Pharma announced that the US health regulator has made six observations after the completion of inspection of active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad.
Facing headwinds in US, Natco Pharma looks to scale up business in China expresspharma
August 13, 2019
Natco Pharma is focusing on filing of cancer treatment drugs in China, the world’s second largest pharmaceutical market, as part of its strategy to diversify business in various emerging markets amid headwinds in the US.
Natco Pharma settles patent litigation with Onyx Therapeutics over cancer drug expressbpd
May 31, 2019
The company said it has reached a settlement agreement with Onyx Therapeutics related to generic versions of 10 mg, 30 mg and 60 mg of Kyprolis
Natco Pharma posts over two-fold jump in Q2 PAT to ₹ 181.6 crore expressbpd
November 06, 2018
The company had posted a consolidated profit after tax of ₹ 84.4 crore in the same quarter
Panacea Biotec inks Tripartite agreement with Natco Pharma, Breckenridge Pharmaceutical expressbpd
August 30, 2018
Panacea Biotec, one of the India’s leading research based pharmaceutical and biotechnology companies, has entered into a tripartite agreement with Natco Pharma and Breckenridge Pharmaceutical.......

Previous page 1 2 Next page